cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Prelude Therapeutics Inc
3 own
4 watching
Current Price
$5.71
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
273.6M
52-Week High
52-Week High
8.9
52-Week Low
52-Week Low
4.2
Average Volume
Average Volume
0.1M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization273.6M
icon52-Week High8.9
icon52-Week Low4.2
iconAverage Volume0.1M
iconDividend Yield--
iconP/E Ratio--
What does the Prelude Therapeutics Inc do?
Prelude Therapeutics Inc is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. Prelude Therapeutics Inc was incorporated under the laws of the State of Delaware in February 2016. Our principal executive offices are located at 200 Powder Mill Road, Wilmington, DE 19803, and our telephone number is (302) 467-1280. Our website address is www.preludetx.com.
Read More
How much money does Prelude Therapeutics Inc make?
News & Events about Prelude Therapeutics Inc.
Globe Newswire
2 months ago
Four differentiated clinical compounds progressing through Phase 1 towards key data milestones Eight abstracts accepted for presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting Cash balance of $201.7 million as of December 31, 2022; runway remains unchanged through...
Globe Newswire
2 months ago
WILMINGTON, Del., March 15, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced a clinical trial collaboration with BeiGene, for future evaluation of its investigational CDK9 inhibitor, PRT2527, in ...
Globe Newswire
3 months ago
WILMINGTON, Del., March 01, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in the Barclays Global Healthcare Conference in Miami, March 14 to 16, 2023. On March 16, at...
Globe Newswire
3 months ago
WILMINGTON, Del., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in three healthcare investment conferences in February. On Tuesday, February 14, at 8:40 a.m...
Frequently Asked Questions
Frequently Asked Questions
What is Prelude Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Prelude Therapeutics Inc shares?
plus_minus_icon
How can I buy Prelude Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Prelude Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Prelude Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Prelude Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Prelude Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Prelude Therapeutics Inc?
plus_minus_icon
What percentage is Prelude Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Prelude Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$5.71
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00